Post-reimbursement price of Ixazomib/Enleri in 2025: Will patient burden be reduced?

Ixazomib is an oral proteasome inhibitor mainly used to treat multiple myeloma. This is a cancer that affects plasma cells and often requires multiple treatments to control the disease. Ixazomib is usually used in adult patients who have received at least one prior treatment and can effectively delay disease progression and improve patient survival and quality of life.

With the launch of ixazomib in China and its inclusion in Class B medical insurance, patients' burden on drug costs is expected to be reduced to a certain extent. According to current information, the common capsule preparation specifications of ixazomib include: 4mg 1 capsule for 3 plates, 3mg 1 capsule for 3 plates, and 2.5mg 1 capsule for 3 plates. The price of each box may be more than 10,000 yuan, which is a considerable financial burden for many patients. However, medical insurance coverage will undoubtedly provide greater support to patients, especially during long-term treatment, and can significantly reduce personal out-of-pocket costs.

After medical insurance, the specific reduction of patient burden will depend on the reimbursement ratio of medical insurance and the patient's specific medication situation. Generally speaking, the reimbursement ratio of Class B medical insurance for drugs is about 50%-70%, which means that patients can get part of the reimbursement when paying for drugs, thereby reducing the financial burden. For example, if the market price of a box of ixazomib is 12,000 yuan, assuming that medical insurance reimburses 60%, the patient only needs to pay 4,800 yuan out of pocket, which is obviously much easier than paying in full.

It is worth noting that because the treatment of multiple myeloma usually requires a long duration, patients may need to purchase the drug repeatedly, so medical insurance coverage is very important to ensure the financial security of patients. In addition, patients should communicate with their doctors regularly when receiving treatment to obtain the latest treatment plans, and pay attention to changes in medical insurance policies in order to better plan their treatment and medication plans.

Reference materials:https://www.ninlaro.com/